Not FDA-Approved — Research Use Only

BPC-157

BPC-157 is a synthetic partial sequence derived from a peptide identified in human gastric juice. Preclinically, it accelerates healing of tendon, ligament, muscle, and gut tissue by promoting fibrobl...

PubChem CID9941957
FormulaC62H98N16O22
Mol. Weight1419.5 g/mol

Sequence

Mechanism of Action

BPC-157 is a synthetic partial sequence derived from a peptide identified in human gastric juice. Preclinically, it accelerates healing of tendon, ligament, muscle, and gut tissue by promoting fibroblast and tenocyte migration, cell survival under oxidative stress, and new blood vessel formation. A 2025 systematic review screened 544 articles and found only 36 met inclusion criteria — 35 preclinical (animal) studies and exactly one small retrospective clinical case series. Published clinical safety data for BPC-157 remains absent; the evidence base is overwhelmingly animal and in-vitro.

Proposed VEGFR2 signalingFAK-paxillin pathway (fibroblast migration)

Research Literature